Aureka Biotechnologies Inc., a California-based artificial intelligence (AI)-empowered biotech company, has successfully raised USD 10 million through a seed financing round led by K2 Venture Partners and Newerli Capital, both China-based private equity funds. The funds will be directed towards the research and development of an AI+high-throughput digital biotechnology macromolecular drug development platform, marking a significant step forward in the integration of AI with biotechnology.
Focus on Innovative Biomedical Development
Founded in March 2023, Aureka has pledged to concentrate on the development of bispecific antibody (BsAb), chimeric antigen receptor (CAR)-T therapy, and antibody drug conjugate (ADC) technologies. The company’s innovative approach leverages AI to enhance the efficiency and effectiveness of drug development processes.
Single-Cell Screening Platform and Microfluidics Technology
Aureka boasts a state-of-the-art single-cell screening platform based on microfluidics technology, which enables the screening of over 100 functional BsAbs from hundreds of millions of possibilities. This technology is a game-changer in the field of biotechnology, as it significantly speeds up the discovery and development of new therapeutics.
The Potential Impact of Aureka’s AI-Driven Approach
The investment in Aureka Biotechnologies highlights the growing interest in AI-driven biotechnology and its potential to revolutionize drug development. With the backing of K2 Venture Partners and Newerli Capital, Aureka is well-positioned to expand its AI+high-throughput digital biotechnology platform and contribute to the advancement of cutting-edge medical treatments.-Fineline Info & Tech
